Reproducibility of nasal potential difference measurements in cystic fibrosis

Chest

Volumn 132, Issue 4, 2007, Pages 1219-1226

  Yaakov, Yasmin ^a   Kerem, Eitan ^a   Yahav, Yaakov ^b   Rivlin, Joseph ^c   Blau, Hannah ^d   Bentur, Lea ^e   Aviram, Micha ^f   Picard, Elie ^g   Bdolah Abram, Tali ^a   Wilschanski, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

^d SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^e RAMBAM MEDICAL CENTER   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Cystic fibrosis; Nasal potential difference; Nonclassic cystic fibrosis

Indexed keywords

AMILORIDE; CHLORIDE; ISOPRENALINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE; OUTCOME ASSESSMENT; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; REPRODUCIBILITY;

EID: 35449001628     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2975     Document Type: Article

References (29)

1. Wilschanski M, Famini H, Strauss-Liviatan N, et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001; 17:1208-1215
2. Pradal U, Castellani C, Delmarco A, et al. Nasal potential difference in congenital bilateral absence of the vas deference. Am J Respir Crit Care Med 1998; 158:896-901
3. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet 2005; 118:372-381
4. Sheth S, Shea JC, Bishop MD, et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003; 113:286-292
5. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement: Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132:589-595
6. Zielenski J. Genotype and phenotype in cystis fibrosis. Respiration 2000; 67:117-133
7. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003; 9:498-503
8. De Boeck K, Wilshanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61:627-635
9. Kerem E, Kalman YM, Yahav Y, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Genet 1995; 96:193-197
10. Kerem E, Rave-Harel N, Augarten A, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997; 155:1914-1920
11. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential techniques and protocols for the assessment of the efficiency of gene transfer in cystic fibrosis. Hum Gene Ther 1995; 6:445-455
12. Schuler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial potential difference measurements. J Cyst Fibros 2004; 3:151-156
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310
14. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004; 37:385-392
15. - conductance. J Membr Biol 1999; 169:175-188
16. Ji HL, Chalfant ML, Jovov B, et al. The cytosolic termini of the beta- and gamma-ENaC subunits are involved in the functional interactions between cystic fibrosis transmembrane conductance regulator and epithelial sodium channel. J Biol Chem 2000; 275:27947-27956
17. Jiang Q, Li J, Dubroff R, et al. Epithelial sodium channels regulate cystic fibrosis transmembrane conductance regulator chloride channels in Xenopus oocyte. J Biol Chem 2000; 275:13266-13274
18. Mall M, Hipper A, Greger R, et al. Wild type but not F508 CFTR inhibits Na+ conductance when coexpressed in Xenopus oocyte. FEBS Lett 1996; 381:47-52
19. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269:847-850
20. Nagel G, Szellas T, Riordan JR, et al. Non-specific activation of the epithelial sodium channel by the CFTR chloride channel. EMBO Rep 2001; 2:249-254
21. Mall M, Kunzelmann K. CFTR: a regulator of the amiloride-sensitive epithelial Na+ channel, ENaC. Available at: http://pen2.igc.gulbenkian.pt/cftr/ vr/e/mall_kunzelmann_cftr_a_regulator_of_the_amiloride_sensitive.pdf. Accessed September 20, 2007
22. Myerburg MM, Butterworth MB, McKenna EE, et al. Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis. J Biol Chem 2006; 281:27942-27949
23. Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6:119-126
24. Stewart B, Zabner J, Shuber AP, et al. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995; 151:899-903
25. Hebestreit A, Kersting U, Basler B, et al. Exercise inhibits epithelial sodium channels in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 164:443-446
26. Cantin AM, Hanrahan JM, Bilodeau G, et al. Cystic fibrosis transmembrane conductace regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006; 173:1139-1144
27. Boyle MP, Diener-West M, Milgram L, et al. A multicenter study of the effect of solution temperature on nasal potential difference. Chest 2003; 124:482-489
28. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patient with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349:1433-1441
29. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in CFTR by nasal aminoglycosides in CF patients with stop mutations. Am J Respir Cell Mol Biol 2007; 37:57-66